GlobeNewswire Inc | Jul 29, 2020 07:05AM EDT

July 29, 2020

NESS ZIONA, Israel, July 29, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (Sol-Gel or the Company), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2020 financial results on Thursday, August 6, 2020 at 7:05 AM ET.

About Sol-Gel Technologies

Sol-Gelis a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.Sol-Gelleverages its proprietary microencapsulation technology platform for Twyneo, for the treatment of acne vulgaris, and Epsolay, for the treatment of papulopustular rosacea. The Companys pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, for the treatment ofpalmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visitwww.sol-gel.com.

For further information, please contact:

Sol-Gel Contact:Gilad MamlokChief Financial Officer+972-8-9313433

Investor Contact:Lee M. SternSolebury Trout +1-646-378-2922lstern@soleburytrout.com

Source: Sol-Gel Technologies Ltd.